source
- Madrigal secures fourth MASH partnership, snapping up Arrowhead drug passed over by J&JMadrigal Pharmaceuticals announced its latest collaboration, marking the fourth deal focused on metabolic dysfunction-associated steatohepatitis (MASH) within a ten‑month span. The agreement bring…
- Expert discusses how clinicians choose between FOLFIRINOX and newly approved NALIRIFOX for metastatic pancreatic cancerDr. Deirdre J. Cohen, director of GI Oncology at Mount Sinai, provides commentary on how doctors decide on frontline chemotherapy for metastatic pancreatic cancer. She notes that, as of 2026, ther…